References
- Yamashita T, Sakamoto K, Yamanishi H, Totani N, Yamamoto J. Effect of a free radical scavenger on nitric oxide release in microvessels. Vascul Pharmacol. 2013;58:134–9.
- Sun YY, Li Y, Wali B, Li Y, Lee J, Heinmiller A, et al. Prophylactic edaravone prevents transient hypoxic-ischemic brain injury: implications for perioperative neuroprotection. Stroke. 2015;46:1947–55.
- Dempsey JA, Forster HV. Mediation of ventilatory adaptations. Physiol Rev. 1982;62:262–346.
- Orr JA, Erichsen DF, Shirer HW, Allen PL, Payne PA. Intravenous acid infusion without lowering arterial pH stimulates breathing. J Appl Physiol. 1986;60:861–7.
- Shams H, Peskar BA, Scheid P. Acid infusion elicits thromboxane A2-mediated effects on respiration and pulmonary hemodynamics in the cat. Respir Physiol. 1988;71:169–83.
- Bower L, Ji M, Apple S, Hoang M, Tran L, Hahn B et al. Summary of the US safety data for Radicava (edaravone): findings from the postmarketing pharmacovigilance. Amyotroph Lateral Scler Frontotemp Degener. 2018;19:359.
- Nefussy B, Vainer B, Fainmesser Y, Drory VE. Early post-marketing experience with edaravone. Amyotroph Lateral Scler Frontotemp Degener. 2018;19: 358–9.
- Maier A, Spittle S, Koch B, Kettemann D, Funke A, Gajewski N, et al. Edaravone therapy in amyotrophic lateral sclerosis (ALS)-initial experience at 4 ALS centres in Germany. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19: 360–1.
- Wong JC, Lomen Hoerth C. Edaravone therapy in ALS: the University of California San Francisco (UCSF) ALS center experience. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:363.
- Brooks BR, Bravver EK, Bockenek WL, Lindblom SS, Jalali N, Dawson WB, et al. Single-site experience in edaravone (Radicava) treatment deployment for amyotrophic lateral sclerosis patients: insurance verification, infusion options, delivery system initiation, safety and monitoring. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19: 361–2.